Dupilumab Offers Hope for Dermatitis Herpetiformis Patients Who Cannot Tolerate Dapsone
Dermatitis herpetiformis (DH) is an autoimmune blistering skin condition that develops in response to dietary gluten. It is closely linked to celiac disease and is characterized by intensely itchy clusters of small blisters, most often appearing on the elbows, knees, back, and buttocks. For most patients, managing the condition involves a strict lifelong gluten-free diet combined with the medication dapsone. But dapsone is not safe for everyone. For patients with certain underlying conditions, the drug can be dangerous or outright contraindicated, leaving a meaningful gap in treatment options that clinicians and patients have long struggled with.
A new case report published in JAAD Case Reports (May 2025) documents the successful use of dupilumab as an alternative treatment for a 21-year-old woman with DH who could not take dapsone due to a rare liver metabolic condition called glycogen storage disease (GSD). Because dapsone is processed by the liver and generates oxidative metabolites, it poses serious risks for patients with GSD. The medical team at Hamad Medical Corporation in Doha, Qatar, led by dermatologist Martin Steinhoff, MD, PhD, and co-author Sara Al-Khawaga, MD, PhD, turned to dupilumab, a biologic therapy already well-established for atopic dermatitis and other inflammatory skin diseases.
Dupilumab works by blocking the IL-4 receptor alpha chain, which is shared by two key inflammation-driving proteins: IL-4 and IL-13. Research has shown that patients with DH have elevated levels of these Th2-type cytokines, suggesting that this pathway plays a meaningful role in driving the disease. By inhibiting IL-4 and IL-13 signaling, dupilumab may reduce the immune cascade responsible for blister formation, eosinophil infiltration, and tissue injury in DH skin. The patient began dupilumab injections at 300 mg every two weeks, following an initial loading dose of 600 mg. Ten weeks into treatment, her itch score had dropped significantly and most lesions had resolved. By week 19, she had zero active lesions and reported a 0 out of 10 itch score. She remained stable on this regimen for two full years of monitoring.
The case adds to a small but growing body of evidence suggesting that dupilumab may be a viable option for DH patients who cannot tolerate conventional therapy. Currently, there is no standardized, evidence-based treatment protocol for dapsone-intolerant patients, which makes this report particularly relevant for the clinicians and patients who face this challenge. The authors note that dupilumab's well-established safety profile makes it an especially attractive candidate for long-term use. While a single case report does not establish dupilumab as standard of care for DH, it offers a compelling foundation for future controlled research into this underserved patient population and brings a practical clinical option into focus for providers who have few alternatives.
Source: JAAD Case Reports, May 8, 2025. Al-Khawaga S, Ahmed AI, Al-Khawaja F, et al. Dermatitis herpetiformis successfully treated with dupilumab. JAAD Case Rep. 2025;61:129-132. doi: 10.1016/j.jdcr.2025.03.037. This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider for guidance specific to your situation.